Showing 591-600 of 993 results for "".
- New Data from Revian Red: System Shown to Support Hair Growthhttps://modernaesthetics.com/news/new-data-from-revian-red-system-shown-to-support-hair-growth/2472868/The Revian Red hair growth system demonstrates the ability to successfully stop hair loss and subsequently grow new hair, according to final data from a randomized, double-blind study. Findings were presented at the 2020 Winter Clinical Dermatology Conference – Hawaii an
- Launching at CES: Next Gen Neutrogena Skin360™ Apphttps://modernaesthetics.com/news/launching-at-ces-next-gen-neutrogena-skin360-app/2472860/Debuting at the Consumer Electronics Showcase (CES) in Las Vegas, the new Neutrogena Skin360™ app combines advanced skin imaging, behavior coaching and artificial intelligence to empower consumers with actionable, personalized steps to help achieve their skin health goals.
- Dr. Roy Geronemus Awarded the Vic Narurkar, MD Innovations in Aesthetic Dermatology Lectureship Awardhttps://modernaesthetics.com/news/dr-roy-geronemus-awarded-the-vic-narurkar-md-innovations-in-aesthetic-dermatology-lectureship-award-1/2472843/Roy Geronemus, MD of Laser & Skin Surgery Center of New York received, The American Society for Dermatologic Surgery inaugural Vic Narurkar, M.D., Innovations in Aesthetic Dermatology Lectureship Award Dr. Geronemus received the award at the 2019 ASDS annual meeting in Chicago. He d
- Galderma Set to Start Seven New Clinical Studieshttps://modernaesthetics.com/news/galderma-set-to-start-begin-seven-new-clinical-studies/2472838/Galderma is initiating seven clinical studies that seek to support potential, new aesthetic indications including a tear trough indication for Restylane, a facial wrinkles indication for Sculptra Aesthetic as well as several studies supporting an investigational liquid neurotoxin and a Phase 2 st
- Results of Phase 2 Study Demonstrate Safety and Efficacy of Galderma's Proprietary Liquid Toxinhttps://modernaesthetics.com/news/results-of-phase-2-study-demonstrate-safety-and-efficacy-of-galdermas-proprietary-liquid/2472827/Results of a Phase 2 study show Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines. Galderma is now poised to advance to Phase 3 testing of the liquid formulation of botulinum toxin type A for the treatment of glabellar lines. The tr
- BTL Gives Back Through New Dress for Success Partnershiphttps://modernaesthetics.com/news/btl-gives-back-through-new-dress-for-success-partnership/2471883/BTL is partnering with Dress for Success, a global not-for-profit organization that provides women with support, professional attire and development tools to help them reenter the work force. This partnership kicks-off a broader marketing effort by BTL – BTL Cares -- which provides
- Galderma Joins Forces with Three Charitieshttps://modernaesthetics.com/news/galderma-joins-forces-with-three-charities/2471904/Galderma is partnering with
- ASAPS: Americans Spent More than $2B on Silicone Gel Breast Implants and Injectables in 2018https://modernaesthetics.com/news/asaps-americans-spent-more-than-2b-on-silicone-gel-breast-implants-and-injectables-in-2018/2471919/Americans spent more than $2 billion on silicone gel breast implants and injectables in 2018 alone, according to new data from The American Society for Aesthetic Plastic Surgery (The Aesthetic Society). Breast
- Galderma's Dysport Celebrates 10 Years Since FDA Approvalhttps://modernaesthetics.com/news/dysport-celebrates-10-years-since-fda-approval/2471921/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in
- MedShift Reports Third Consecutive Year of Growthhttps://modernaesthetics.com/news/medshift-reports-third-consecutive-year-of-growth/2471950/MedShift has achieved its third consecutive year of 300% year-over-year growth and advancement of its patient-facing vConfidence and Effronte brands, according to